English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17938/22957 (78%)
Visitors : 7398381      Online Users : 297
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24429


    Title: Cedrol suppresses glioblastoma progression by triggering DNA damage and blocking nuclear translocation of the androgen receptor
    Authors: Chang, KF;Huang, XF;Chang, JHT;Huang, YC;Weng, JC;Tsai, NM
    Keywords: Cedrol;Glioblastoma;Androgen receptor;DNA damage;Temozolomide
    Date: 2020
    Issue Date: 2022-08-09T08:02:10Z (UTC)
    Publisher: ELSEVIER IRELAND LTD
    ISSN: 0304-3835
    Abstract: Glioblastoma (GBM) is the most common and aggressive primary brain tumor with great invasiveness and resistance to chemotherapy, which presents a treatment challenge. In this study, we investigated the antitumor effect of Cedrol, a sesquiterpene alcohol isolated from Cedrus atlantica, against GBM cells in vitro and in vivo. Cedrol was found to potently inhibit cell growth and induce intracellular ROS generation and DNA damage response. In addition, Cedrol induced significant G(0)/G(1) cell cycle arrest and cell apoptosis via the extrinsic (Fas/FasL/Caspase-8) and intrinsic (Bax/Bcl-2/Caspase-9) pathways. In addition, Cedrol had a synergistic effect with temozolomide (TMZ) and reduced drug resistance by blockage of the AKT/mTOR pathway. Cedrol suppressed tumor growth in both orthotopic and xenograft GBM animal models with low or no short-term acute toxicity or long-term accumulative toxicity. In a molecular docking study, Cedrol targeted the androgen receptor (AR), and reduced DHT-mediated AR nuclear translocation, downstream gene KLK3/TMPRSS2 expression and cell proliferation. Our study demonstrates that Cedrol may be a potential candidate for drug development for single or combination treatment with TMZ in GBM therapy.
    URI: http://dx.doi.org/10.1016/j.canlet.2020.09.007
    https://www.webofscience.com/wos/woscc/full-record/WOS:000590213100002
    https://ir.csmu.edu.tw:8080/handle/310902500/24429
    Relation: CANCER LETTERS ,2020 ,v495 ,p180-190
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML225View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback